Measurable residual disease in the treatment of chronic lymphocytic leukemia
|
| |
Authors: | Takayoshi Uchiyama Aki Yokoyama Sadao Aoki |
| |
Affiliation: | Niigata University of Pharmacy and Applied Life Sciences, Faculty of Pharmaceutical Sciences, Department of Pathophysiology, Niigata, Japan |
| |
Abstract: | Treatment outcomes of chronic lymphocytic leukemia (CLL) have improved since chemoimmunotherapy and novel drugs became available for CLL treatment; therefore, more sensitive methods to evaluate residual CLL cells in patients are required. Measurable residual disease (MRD) has been assessed in several clinical trials on CLL using flow cytometry, real-time quantitative PCR (RQ-PCR) with allele-specific oligonucleotide (ASO) primers, and high-throughput sequencing. MRD assessment is useful to predict the treatment outcomes in the context of chemotherapy and treatment with novel drugs such as venetoclax. In this review, we discuss major techniques for MRD assessment, data from relevant clinical trials, and the future of MRD assessment in CLL treatment. |
| |
Keywords: | measurable residual disease chronic lymphocytic leukemia multicolor flow cytometry ibrutinib venetoclax |
|
|